Last updated: February 21, 2026
What is PERIDEX?
PERIDEX is a topically applied antimicrobial oral rinse containing chlorhexidine gluconate, primarily used for periodontal disease treatment. Approved by the FDA, it is manufactured by Colgate-Palmolive. The drug generates revenue within the dental and periodontal care segments and faces competition from other chlorhexidine-based products.
Market Overview
Market Size and Growth
The global periodontal disease market was valued at approximately $3.2 billion in 2021, with a compound annual growth rate (CAGR) forecast of 4.5% through 2028 (Grand View Research, 2022). The antimicrobial oral rinse segment remains dominant, driven by increasing awareness of oral health and aging populations.
Key Players
- Colgate-Palmolive (PERIDEX)
- GlaxoSmithKline (ologen, Peridex competitors)
- Sunstar
- Others
Competitive Landscape
PERIDEX faces competition from generic chlorhexidine rinses, alternative prescription oral hygiene products, and emerging antimicrobial agents. Market preference is influenced by efficacy, safety profile, and product marketing.
Financials and Sales Data
Revenue Contribution
Since PERIDEX is a prescription product, its sales depend on prescriber preferences and insurance reimbursement patterns. Colgate reports specific data for dental sprays and rinses, but detailed sales for PERIDEX are not publicly disclosed.
Pricing and Reimbursement
The average wholesale price (AWP) for PERIDEX ranges between $15 and $20 per 8 oz bottle. Reimbursement rates are determined by insurance coverage, impacting net sales.
Patent and Regulatory Status
PERIDEX's primary patent expired in 2014, allowing generic competition. However, regulatory protections include exclusivity for certain formulations and indications, and brand loyalty sustains sales.
Investment Fundamentals
Market Penetration and Growth Potential
PERIDEX retains a significant share in the prescription antimicrobial rinse segment due to prescriber familiarity. Growth depends on:
- Expansion of dental practices prescribing antiseptic rinses
- Increasing awareness of periodontal health
- Demographic trends favoring aging populations
Competitive Risks
Generic competition limits pricing power and profit margins. New formulations or alternative therapies in periodontal care could erode market share.
Innovation and Pipeline
Colgate has not announced new formulations or indications specifically for PERIDEX. The company's focus on broader oral health ensures continued support but not necessarily pipeline expansion for this product.
Regulatory Environment
No recent changes threaten PERIDEX's approval status, but ongoing scrutiny over antimicrobial resistance could influence future regulations affecting chlorhexidine products.
Investment Outlook
- Stable Cash Flow Potential: Mature product with consistent demand in dental offices.
- Limited Growth: Lacks significant innovation or expansion scope due to patent expiration and generics.
- Competitive Pressure: Price erosion from generics and preference shifts.
- Market Risks: Regulatory changes or market entry of new antimicrobial agents.
Key Financial Metrics (Hypothetical Estimates)
| Metric |
Estimated Value |
Notes |
| Annual sales (approximate) |
$100-150 million |
Based on prescriber utilization and pricing data |
| Market share in prescription segment |
~20-25% |
Stabilized due to brand loyalty and prescriber familiarity |
| Gross profit margin |
60-65% |
Typical for branded oral care products |
| R&D spend for formulation/indications |
Minimal |
No significant recent R&D investments |
Strategic Considerations
- Maintaining prescriber relationships.
- Leveraging marketing channels for oral health awareness.
- Monitoring regulatory developments affecting antimicrobial products.
- Exploring new indications or formulations for longevity.
Key Takeaways
- PERIDEX operates in a mature segment with steady demand but limited growth potential.
- Patent expiry and generic competition constrain pricing and profit margins.
- The product's revenue stability depends on prescriber habits and insurance coverage.
- There is a nominal entry barrier against competitors due to brand recognition.
- Future risk factors include regulatory pressures and market penetration challenges.
FAQs
-
What is the primary compound in PERIDEX?
Chlorhexidine gluconate.
-
How long has PERIDEX been on the market?
Since approved by FDA around 1988, with patent expiration in 2014.
-
What are the main risks for investors in PERIDEX?
Patent expiration, generic competition, regulatory changes, and decreasing prescriber preference.
-
Is there potential for new indications or formulations?
Currently no significant pipeline; focus remains on maintaining market share.
-
How does insurance influence PERIDEX sales?
Insurance reimbursement affects affordability and prescriber prescribing patterns.
References
- Grand View Research. (2022). Periodontal Disease Market Size, Share & Trends Analysis Report.
- Colgate-Palmolive Annual Reports (2012–2021).
- U.S. Food and Drug Administration. (2014). Peridex and PerioGard Labeling Changes.
